New cocktail aims to shrink Hard-to-Treat ovarian tumors
NCT ID NCT07239622
First seen Nov 20, 2025 · Last updated Apr 30, 2026 · Updated 27 times
Summary
This study tests a combination of three drugs—liposomal irinotecan, sintilimab, and anlotinib—in people with a rare and aggressive ovarian cancer called ovarian clear cell carcinoma that has come back or not gone away after standard treatment. The goal is to see if this drug mix can shrink tumors and how safe it is. About 36 adults will take part across multiple hospitals.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.